Login to Your Account

Clinic Roundup

Wednesday, April 20, 2011
Vicept Therapeutics Inc., of Malvern, Pa., said results from a Phase II trial testing the dose-response relationship of two concentrations of V-101, a topical cream for treating Type I rosacea demonstrated a statistically significant improvement (p < 0.01) in the primary endpoint, defined as a reduction in facial erythema over a 12-hour period vs. placebo cream. V-101 also demonstrated a safety profile similar to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription